Cargando…
Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
OBJECTIVES: Belimumab, an anti-B lymphocyte stimulator (BLyS) human monoclonal antibody, was approved in the United States, Canada and European Union for the treatment of the patients with systemic lupus erythematosus (SLE). However, belimumab had not been evaluated in Japanese patients. The objecti...
Autores principales: | Yamada, Masanori, Akita, Mikio, Nakagawa, Tomofumi, Takahashi, Naoki, Endo, Akira, Yoshida, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Maney Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937663/ https://www.ncbi.nlm.nih.gov/pubmed/27536436 http://dx.doi.org/10.3109/21556660.2013.792823 |
Ejemplares similares
-
Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020) -
Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017) -
Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015) -
Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016) -
Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study
por: Zhang, Jing, et al.
Publicado: (2020)